Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Immune System Diseases × Plasmalyte A × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Immune System Diseases 1

Interventions

Cyclophosphamide 13 fludarabine 8 fludarabine phosphate 7 Busulfan 5 Tacrolimus 4 Mycophenolic Acid 4 Bendamustine Hydrochloride 4 Rituximab 3 Melphalan 3 Bortezomib 3 ponatinib 2 pembrolizumab 2 ibrutinib 2 cobomarsen 2 Whole-Body Irradiation 2 Vorinostat 2 Vincristine 2 Prednisone 2 Peripheral Blood Stem Cell Transplantation 2 Patient Reported Outcome Measures 2 Mesna 2 Etoposide 2 Doxorubicin 2 Brentuximab Vedotin 2 AP 1903 reagent 2 thymoglobulin 1 tetulomab tetraxetan lu-177 1 palbociclib 1 ibritumomab tiuxetan 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02519816 2019-08-14

CARE

Maisonneuve-Rosemont Hospital

Phase 2 Unknown

Immune System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡